Why is TheraCryf Plc ?
Unrated Stock - No Analysis Available
Quality key factors
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
6.58%
EBIT to Interest (avg)
-3.52
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.69
Sales to Capital Employed (avg)
0.15
Tax Ratio
6.91%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.94
EV to EBIT
-0.45
EV to EBITDA
-0.46
EV to Capital Employed
0.78
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-171.90%
ROE (Latest)
-41.84%
Technical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
Bullish
Bollinger Bands
Sideways
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Technical Movement
5What is working for the Company
OPERATING CASH FLOW(Y)
Highest at GBP -4.78 MM
NET PROFIT(HY)
Higher at GBP -1.31 MM
EPS(Q)
Highest at GBP -0
-1What is not working for the Company
RAW MATERIAL COST(Y)
Grown by 101.03% (YoY
Here's what is working for TheraCryf Plc
Net Profit
Higher at GBP -1.31 MM
than preceding 12 month period ended Sep 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (GBP MM)
Operating Cash Flow
Highest at GBP -4.78 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (GBP MM)
EPS
Highest at GBP -0
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (GBP)
Here's what is not working for TheraCryf Plc
Raw Material Cost
Grown by 101.03% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales






